Screener
Vera Therapeutics VERA Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Vera Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:33 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212143
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accretion of discount and amortization of premium on purchase of debt securities | (843) | (2,531) |
| Accretion of loan exit fee and amortization of loan costs | 639 | 221 |
| Reduction in the carrying amount of operating lease right-of-use assets | 116 | 457 |
| Stock-based compensation | 13,208 | 7,744 |
| Upfront and milestone obligations under license agreements | 15,000 | 750 |
| Changes in operating assets and liabilities: | ||
| Prepaid expense and other current assets | (5,143) | (5,876) |
| Other assets | — | 17 |
Item 1. Financial Statements
FAQ
- What is Vera Therapeutics's stock-based comp?
- Vera Therapeutics (VERA) reported stock-based comp of $13.21M in Q1 2026.
- How has Vera Therapeutics's stock-based comp changed year-over-year?
- Vera Therapeutics's stock-based comp increased by 70.6% year-over-year, from $7.74M to $13.21M.
- What is the long-term trend for Vera Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Vera Therapeutics's stock-based comp has grown at a 88.4% compound annual growth rate (CAGR), from $3.01M to $37.93M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Vera Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude